Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 4.87 | — | — | — | — | — | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.56 | — | — | — | — | — | 0.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.97 | 1.10 | 1.17 | 1.24 | 1.71 | 1.06 | 0.63 | 1.45 | 2.52 | 2.32 | 2.52 | 1.14 | 1.09 | 2.24 | 0.70 | 0.57 | 0.46 | 0.59 | 0.58 | 0.99 | 1.40 |
| — | +4.0% | +85.0% | -15.0% | -32.2% | -54.1% | -74.9% | +27.3% | +131.8% | +3.2% | +258.6% | +101.7% | +136.1% | +282.9% | +20.6% | -42.6% | -67.1% | -66.7% | -81.3% | -73.7% | -57.8% | |
| P/FCF | 3.68 | — | — | — | — | — | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 5.28 | — | — | — | — | — | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 5.37 | — | — | — | — | — | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.5% | — | — | — | — | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 28.4% | — | — | — | — | — | 77.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | 32.0% | — | — | — | — | — | 80.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.9% | -9.9% | -8.3% | -12.7% | -6.6% | -7.7% | 50.3% | -17.7% | -14.9% | -18.5% | -16.5% | -15.5% | -21.3% | -21.2% | -19.5% | -16.9% | -15.2% | -14.1% | -13.8% | -12.5% | -14.9% |
| — | -28.3% | -116.6% | +28.3% | +56.0% | +58.3% | +405.1% | -14.4% | +29.8% | +12.9% | +15.5% | +8.7% | -40.1% | -50.4% | -41.0% | -35.8% | -1.6% | -9.2% | -34.5% | -75.0% | -179.4% | |
| ROA | 16.8% | -7.7% | -6.5% | -10.1% | -5.2% | -6.2% | 37.8% | -12.3% | -10.8% | -13.6% | -12.1% | -11.7% | -15.7% | -15.0% | -14.3% | -12.5% | -11.4% | -11.0% | -10.9% | -9.9% | -12.5% |
| — | -24.6% | -117.3% | +18.1% | +51.5% | +54.7% | +412.5% | -4.6% | +31.4% | +9.2% | +15.4% | +6.3% | -37.9% | -36.8% | -31.0% | -26.3% | +8.5% | +4.1% | -15.8% | -48.1% | -142.5% | |
| ROIC | 16.6% | -9.7% | -8.4% | -11.7% | -6.9% | -10.7% | 61.2% | -16.5% | -13.7% | -16.2% | -16.0% | -16.6% | -21.3% | -19.6% | -16.5% | -15.1% | -14.2% | -12.8% | -12.6% | -10.9% | -12.4% |
| — | +9.2% | -113.7% | +28.9% | +49.4% | +33.8% | +481.2% | +0.7% | +35.7% | +17.4% | +2.7% | -10.4% | -49.5% | -53.1% | -30.8% | -38.5% | -14.9% | -24.7% | -54.1% | -75.7% | -149.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.18 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.27 | 0.24 | 0.21 | 0.24 | 0.22 | 0.19 | 0.33 | 0.28 | 0.24 | 0.22 | 0.19 | 0.16 | 0.15 | 0.13 |
| — | +12.9% | +12.4% | -37.2% | -33.9% | -26.9% | -35.2% | +22.9% | +21.8% | -34.2% | -15.8% | -10.9% | -10.4% | +71.9% | +70.8% | +67.4% | +64.3% | +242.9% | +223.0% | +411.5% | +396.0% | |
| Debt / EBITDA | 0.93 | — | — | — | — | — | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.42 | 7.28 | 8.46 | 8.42 | 8.94 | 8.73 | 9.24 | 4.92 | 5.55 | 6.87 | 7.05 | 6.82 | 9.76 | 6.69 | 8.40 | 8.37 | 7.14 | 8.55 | 9.67 | 9.12 | 9.16 |
| — | -16.6% | -8.4% | +71.2% | +61.0% | +27.0% | +31.1% | -27.9% | -43.1% | +2.7% | -16.1% | -18.5% | +36.7% | -21.8% | -13.1% | -8.3% | -22.1% | -25.9% | -39.2% | -59.4% | -69.1% | |
| Quick Ratio | 8.42 | 7.28 | 8.46 | 8.42 | 8.94 | 8.73 | 9.24 | 4.92 | 5.55 | 6.87 | 7.05 | 6.82 | 9.76 | 6.69 | 8.40 | 8.37 | 7.14 | 8.55 | 9.67 | 9.12 | 9.16 |
| — | -16.6% | -8.4% | +71.2% | +61.0% | +27.0% | +31.1% | -27.9% | -43.1% | +2.7% | -16.1% | -18.5% | +36.7% | -21.8% | -13.1% | -8.3% | -22.1% | -25.9% | -39.2% | -59.4% | -69.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BDTX stock.
Black Diamond Therapeutics, Inc.'s current P/E is 4.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Black Diamond Therapeutics, Inc.'s current operating margin is 28.4%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Black Diamond Therapeutics, Inc.'s business trajectory between earnings reports.